SEARCH RESULTS FOR:
The Next Billion Dollar Biotech Companies
At a time when healthcare is desperately in need of new innovation, AI platform companies are generating a lot of excitement.
Abraham Heifets
CO-FOUNDER AND CEO, ATOMWISE
Atomwise leverages AI for structure-based small molecule drug discovery, removing the barriers of physical screening that have limited the success of traditional methods.
Charles Fisher
FOUNDER AND CEO, UNLEARN.AI
Unlearn.AI is creating a computer simulation of patients to create a digital twin so as to reduce by half the number of patients required for clinical trials.
Peter Staartjes
CEO, ANDINO HOLDINGS
Andino Holdings comments on the factors influencing the chemical distribution market in Latin America for 2020.
Carlos Amaral
GENERAL MANAGER, ACREP ANGOLA E&P
Acrep Angola E&P analyses the difficulties of expanding in Angola during the pandemic and with lower oil prices.
Edmundo Puentes
BOARD MEMBER, OXIQUIM & PRESIDENT, ASIQUIM
Oxiquim speaks to GBR about the current trends in Chile’s petrochemical market.
Gianflavio Carozzi
CEO, AESA
ASEA speaks of the importance of training to ensure safe and efficient operations.
Peter Quarm
DIRECTOR, DUTYLEX
Dutylex explains the challenges of beginning a business distributing industrial lubricants in Ghana and West Arica more generally.
Martin van Gemert
MANAGING DIRECTOR, MINCON WEST AFRICA
Mincon comments on its business with the mining sector in West Africa.
Tim Gabruch
VP COMMERCIAL, DENISON MINES CHIEF COMMERCIAL OFFICER, URANIUM PARTICIPATION CORPORATION
Uranium Report 2020
“Phoenix is the highest-grade undeveloped uranium deposit in the world, with an average grade of 19.1% and 59.7 million pounds U3O8 in probable reserves (141,000 tonnes).”
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
